APTA - Ticker AI Digest

Aptamer Group PLC
0.62 | Today -0.80%
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (APTA) 0
No same-day market news for APTA on 2026-04-15.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
APTA 06:01
Aptamer Group PLC
Launch of targeted radiopharmaceutical programme
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Aptamer Group PLC launches a targeted radiopharmaceutical programme in collaboration with Radiopharmium Ltd, aiming to develop four radiotherapy assets by 2026. The programme focuses on three high-value clinical targets using Optimer® radioconjugates, addressing limitations in current radiopharmaceuticals like stability and shelf life. Comparative <mark style="background-color:yellow">test</mark>s show Optimer®-based radioligands have superior stability, potentially reducing waste and simplifying logistics. Led by Dr. Louis Allott, the initiative leverages Radiopharmiums expertise and preclinical models, positioning Aptamer to advance assets toward in vivo validation in a rapidly growing $7.5 billion market.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 4
APTA 06:01
Aptamer Group PLC
Result of Retail Offer and Posting of Notice of GM
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Aptamer Group PLC announced the results of its Retail Offer and the posting of the notice of General Meeting. The Retail Offer raised approximately £274,000, with a total of £4.5 million raised through the Placing, Subscription, and Retail Offer. The funds are subject to the approval of certain resolutions at the General Meeting scheduled for April 13, 2026. The company, a leading developer of next-generation synthetic binders for the life sciences industry, will issue 45,665,573 Retail Offer Shares at 0.6p per share. The announcement also includes important notices regarding the offers restrictions, forward-looking statements, and product governance requirements.
APTA 06:06
Aptamer Group PLC
Retail Offer to raise up to £0.5 million
APTA 06:01
Aptamer Group PLC
Results of Placing
APTA 06:01
Aptamer Group PLC
Proposed Placing, Subscription and Retail Offer
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
APTA 06:11
Aptamer Group PLC
Interim Results and Notice of Investor Webinar
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC, a developer of synthetic binders for the life sciences industry, reported its interim results for the six months ended 31 December 2025. Key highlights include
**Financial Performance** Revenue increased by 27% to £0.83 million, with an adjusted EBITDA loss reduced to £1.0 million. A successful £1.8 million fundraising in July 2025 and a cash balance of £1.5 million at the period end provide a cash runway through Q2 2027.
**Strategic Advances** Progress in enzyme-modulating Optimers, immunohistochemistry reagents, and therapeutic programs, including a fibrotic liver delivery vehicle with promising preclinical results. Partnerships with Twist Bioscience, Alphazyme, and Unilever are advancing.
**Fee-for-Service Contracts** Secured significant contracts, including a £360,000 deal in radioligand therapy and £769,000 from a top 5 pharmaceutical partner, marking strategic entries into high-growth sectors.
**Post-Period Developments** Launched Optimer-containing kits, initiated a radioligand therapy program with Radiopharmium, and announced an Accelerated Book Build to raise at least £3.75 million, extending the cash runway to 2028.
**Outlook** Focus on converting the asset portfolio into recurring revenues, deepening partnerships, and maintaining cost discipline. The company is confident in its ability to deliver sustainable long-term value to shareholders.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 7
APTA 12:09
Aptamer Group PLC
Result of General Meeting
APTA 06:01
Aptamer Group PLC
Result of Retail Offer and Posting of Notice of GM
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Aptamer Group PLC announced the results of its Retail Offer and the posting of the notice of General Meeting. The Retail Offer raised approximately £274,000, with a total of £4.5 million raised through the Placing, Subscription, and Retail Offer. The funds are subject to the approval of certain resolutions at the General Meeting scheduled for April 13, 2026. The company, a leading developer of next-generation synthetic binders for the life sciences industry, will issue 45,665,573 Retail Offer Shares at 0.6p per share. The announcement also includes important notices regarding the offers restrictions, forward-looking statements, and product governance requirements.
APTA 06:06
Aptamer Group PLC
Retail Offer to raise up to £0.5 million
APTA 06:01
Aptamer Group PLC
Results of Placing
APTA 06:11
Aptamer Group PLC
Interim Results and Notice of Investor Webinar
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Aptamer Group PLC, a developer of synthetic binders for the life sciences industry, reported its interim results for the six months ended 31 December 2025. Key highlights include
**Financial Performance** Revenue increased by 27% to £0.83 million, with an adjusted EBITDA loss reduced to £1.0 million. A successful £1.8 million fundraising in July 2025 and a cash balance of £1.5 million at the period end provide a cash runway through Q2 2027.
**Strategic Advances** Progress in enzyme-modulating Optimers, immunohistochemistry reagents, and therapeutic programs, including a fibrotic liver delivery vehicle with promising preclinical results. Partnerships with Twist Bioscience, Alphazyme, and Unilever are advancing.
**Fee-for-Service Contracts** Secured significant contracts, including a £360,000 deal in radioligand therapy and £769,000 from a top 5 pharmaceutical partner, marking strategic entries into high-growth sectors.
**Post-Period Developments** Launched Optimer-containing kits, initiated a radioligand therapy program with Radiopharmium, and announced an Accelerated Book Build to raise at least £3.75 million, extending the cash runway to 2028.
**Outlook** Focus on converting the asset portfolio into recurring revenues, deepening partnerships, and maintaining cost discipline. The company is confident in its ability to deliver sustainable long-term value to shareholders.
APTA 06:01
Aptamer Group PLC
Proposed Placing, Subscription and Retail Offer
APTA 06:01
Aptamer Group PLC
Launch of targeted radiopharmaceutical programme
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Aptamer Group PLC launches a targeted radiopharmaceutical programme in collaboration with Radiopharmium Ltd, aiming to develop four radiotherapy assets by 2026. The programme focuses on three high-value clinical targets using Optimer® radioconjugates, addressing limitations in current radiopharmaceuticals like stability and shelf life. Comparative <mark style="background-color:yellow">test</mark>s show Optimer®-based radioligands have superior stability, potentially reducing waste and simplifying logistics. Led by Dr. Louis Allott, the initiative leverages Radiopharmiums expertise and preclinical models, positioning Aptamer to advance assets toward in vivo validation in a rapidly growing $7.5 billion market.

AI Crunch

Single-Ticker AI Crunch
APTA signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Aptamer Group PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full APTA AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for APTA on 2026-04-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
20126800
Enterprise Value
43277928
Public Float
66.72
Broker Target
180
Shares Out
3157145044
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BNRRP542
Market
None
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-09
Net Debt
-568000.0
Cash
1059000.0
EPS
-
Net Income
-2424000.0
Revenue
1203000.0
Enterprise Value
43277928
Trailing PE
-
Forward PE
-
Price Sales TTM
14.6058
Price Book MRQ
8.4078
EV Revenue
12.8794
EV EBITDA
-5.0596

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
26.5526
Institutions As Of
2025-08-07
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
0
Purchase TR1
4
Sale TR1
2
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

AI Charts is armed for the next catalyst in APTA.

No same-day headline has printed on 2026-04-15 yet, but the latest digestion is ready below the chart workflow and the catalyst beacons can still map the recent tape.
Standby Tape Data 2026-04-15 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
0 Today
Catalyst Pulse
Waiting for a fresh same-day headline while recent digestion stays on deck.
12:09 Latest Tape Result of General Meeting 06:06 Latest Tape Retail Offer to raise up to £0.5 million
AI Charts Studio
APTA Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-04-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 51.61%
RSI Gauge
Price Change
AI Forecast